

A NOVEL QUANTITATIVE ASSAY FOR HIV-1 IN PLASMA

Betty Wu, Huilin Lee, Lijie Gong, Crystal Nguyen, S Brahmasandra NeuMoDx Molecular, Ann Arbor, MI

BACKGROUND

With the success of antiretroviral therapy (ART), more individuals are now living with HIV-1 infection globally. Routine viral load is recommended by WHO as the gold standard in treatment monitoring, diagnosing, and confirming ART failure. However, the genetic heterogeneity of HIV-1 presents a significant challenge to the development of assays capable of reliably detecting and quantifying HIV-1 nucleic acid. While certain subtypes dominate in specific regions, studies show that the spread of different HIV-1 groups and subtypes is increasing globally. Although many commercial tests are currently available on the market, there is a continuous need for HIV monitoring tests with expanded variant coverage, improved workflow, reduced costs, and improved sensitivity. The NeuMoDx HIV-1 Quant Assay is highly sensitive with broad HIV-1 variant inclusivity, and is designed to be implemented on the fully automated NeuMoDx Molecular Systems. These systems provide a "sample to result" type *in-vitro* diagnostic workflow by incorporating efficient RNA extraction coupled with a sensitive real-time RT-PCR assay to deliver highly accurate results using all room temperature stable reagents. Performance of the NeuMoDx HIV-1 Quant Assay was characterized in plasma and is reported here.


RESULTS

The NeuMoDx HIV Assay demonstrated a limit of detection (LoD) and a lower limit of quantitation (LLoQ) of ~20 IU/mL in plasma. The NeuMoDx HIV-1 Test showed excellent linearity across a 6-log dynamic range ($R^2 > 0.98$) with upper limit of quantitation (ULoQ) of ~1E7 Log₁₀ IU/mL. No cross-reactivity was observed against HIV-2 and 34 non-target pathogens tested. Equivalent performance was demonstrated across all the HIV variants, including groups K, O, and CRF isolates from the EQAPOL panel. Finally, a preliminary method correlation study using > 50 clinical residual HIV positive plasma specimens demonstrated excellent concordance between the NeuMoDx HIV-1 Quant Assay and the Roche Cobas® HIV-1 Assay with a bias <0.5 Log₁₀ IU/mL.

Limit of Detection and LLoQ

The Limit of Detection of the NeuMoDx HIV-1 Quant Assay was determined with pooled HIV-1 negative plasma spiked with 4th WHO International HIV-1 Standard at 6 different levels including negative samples. The limit of detection of HIV-1 was determined to be 18.5 IU/mL based on Probit style analysis.

Limit of Quantitation was defined as the concentration of target detected consistently (≥95% sensitivity) with a total analytic error, TAE (bias + 2*SD) ≤ 1. As seen from data in the Table, TAE remains < 1.0 even at 10 IU/mL (below LoD level), since the LLoQ cannot be less than LoD, the calculated LLoQ was determined to be same as LoD and equal to 18.5 IU/mL.



| NeuMoDx HIV-1 Assay Limit of Detection and LLoQ | | | | | | | | | |
|---|--|-------------------------------------|----|-------|-------|---|------|-----------|------|
| Target Conc. (IU/mL) | Target Conc. (Log ₁₀ IU/mL) | HIV Conc. (Log ₁₀ IU/mL) | N | # Pos | % Pos | LoD (Probit) | SD | Abs. Bias | TAE |
| 78 | 1.89 | 1.99 | 16 | 16 | 100 | 18.5 IU/mL 95% CI (12.5-54.4 IU/mL) | 0.17 | 0.10 | 0.43 |
| 30 | 1.48 | 1.37 | 16 | 16 | 100 | | 0.28 | 0.11 | 0.66 |
| 20 | 1.30 | 1.29 | 16 | 15 | 94 | | 0.33 | 0.01 | 0.67 |
| 10 | 1.00 | 1.15 | 16 | 13 | 81 | | 0.26 | 0.15 | 0.67 |
| 5 | 0.70 | 1.27 | 16 | 8 | 50 | | 0.32 | 0.57 | 1.21 |
| 0 | 0 | 0.00 | 8 | 0 | 0 | | - | - | - |

CONCLUSIONS

The NeuMoDx HIV-1 Quant Assay demonstrated sensitive and accurate performance in quantitation of HIV-1 in plasma. The room temperature stable reagents coupled with the rapid turnaround times provide an extremely attractive workflow for implementation on automated system.

METHODS

Multiple primers and probes targeting two highly conserved regions in the HIV-1 genome were employed in the NeuMoDx HIV-1 Quant Assay to ensure robust detection of all groups and subtypes as well as CRF isolates. The objective of this study was to demonstrate performance of the NeuMoDx HIV-1 Quant Assay across key analytical metrics including analytical sensitivity (LoD), linearity, and HIV-1 variant coverage. Evaluation of the analytical sensitivity was performed using the 4th WHO International Standard for HIV-1, and the limits of quantitation (LLoQ/ULoQ) were determined using the TAE ≤ 1.0 criterion. The capability of the assay in detecting HIV variants, including M, O and N subtypes and multiple CRF and drug resistant isolates, was also evaluated with EQAPOL panels. The clinical sensitivity was demonstrated, in a pilot internal study, using residual clinical HIV-1-positive specimens tested with a FDA-cleared test. The entire test was performed using room temperature stable extraction and RT-PCR reagents.

NEUMODX HIV-1 QUANT ASSAY

The NeuMoDx HIV-1 Quant Assay is designed to be a quantitative assay for the detection of HIV-1 in plasma. The assay to be implemented on NeuMoDx Molecular System incorporates automated RNA extraction coupled with real-time reverse transcription polymerase chain reaction rt-PCR to detect two targets in the HIV-1 genome. An universal exogenous sample process control, SPC2, is incorporated in each test to monitor the efficiency of RNA extraction, rt-PCR, and the presence of potential inhibitors. The entire process takes only 95 minutes with minimal hands on time.

HIV-1 Variant Coverage

Detection of HIV-1 variants by the NeuMoDx HIV-1 Quant Assay was evaluated with all the major HIV-1 groups and subtypes as well as multiple circulating recombinant form (CRF) variants from External Quality Assurance Program Oversight Laboratory (EQAPOL).

HIV-1 variant stocks were diluted down to the concentrations indicated in the table with negative plasma.


NeuMoDx HIV-1 Quant Assay demonstrated broad variant coverage with excellent sensitivity, including type O and P.

| NeuMoDx HIV-1 Quant Assay Variant Coverage (Inclusivity) | | | | | | | |
|--|---------------|----------------|-------------|--------------------|---------------|----------------|-------------|
| EQAPOL Panel # | Group/Subtype | HIV Conc. c/mL | % POS (N=6) | EQAPOL Panel # | Group/Subtype | HIV Conc. c/mL | % POS (N=6) |
| DEMA07UG005.S1 | A1 | 20 | 100% | SeraCare 0315-0062 | K | 20 | 100% |
| DEMB10CN002.D1 | B | 20 | 100% | DEOXXDE004.S1 | O | 20 | 100% |
| DEMBF09ES006.D1 | BF | 20 | 100% | DEOXXES001.S1 | O | 20 | 100% |
| DEMC07AO001.S1 | C | 40 | 100% | DEPXXFR006.S1 | P | 20 | 100% |
| DEMC07BR003.D1 | C | 40 | 100% | DE00112CN011.S1 | CRF01_AE | 20 | 100% |
| DEMC09ZA009.D1 | C | 20 | 100% | DE00208CM004.S1 | CRF01_AE | 20 | 100% |
| DEMC96BW002.S1 | C | 40 | 100% | DE00110CN001.S1 | CRF01_AE | 40 | 100% |
| DEMD07UG002.D1 | D | 40 | 100% | DE00110CN009.S1 | CRF01_AE | 40 | 100% |
| DEMD08UG001.D1 | D | 20 | 100% | DE00112CN011.S1 | CRF01_AE | 40 | 100% |
| DEMD10CM009.D1 | D | 40 | 100% | DE00208CM004.S1 | CRF01_AE | 40 | 100% |
| DEMD11UG003.S1 | D | 40 | 100% | DE00109CN003.D1 | CRF01_AE | 40 | 100% |
| DEMF110BR015.S1 | F1 | 40 | 100% | DE00206AO001.D1 | CRF02_AG | 40 | 100% |
| DEURF11CM026.S1 | F1, F2 | 40 | 100% | DE00208CM001.S1 | CRF02_AG | 20 | 100% |
| DEMF210CM001.D1 | F2 | 40 | 100% | DE00208CM004.D1 | CRF02_AG | 40 | 100% |
| DEMG05ES001.S1 | G | 40 | 100% | DE00212FR004.S1 | CRF02_AG | 40 | 100% |
| DEMG09ES002.D1 | G | 20 | 100% | DEURF07ES002.D1 | CRF02_AG | 40 | 100% |
| DEMG09KE001.S1 | G | 40 | 100% | DEURF07UG006.D1 | AD | 20 | 100% |
| DEMG10CM008.S1 | G | 40 | 100% | | | | |

Linearity of NeuMoDx HIV-1 Quant Assay

The linearity of the NeuMoDx HIV-1 Quant Assay was determined by diluting purified HIV-1 stocks subtype B (EQAPOL) in pooled HIV-1 negative plasma to create a panel spanning 6 logs of HIV-1 concentrations ranging from 1.2 Log₁₀ IU/mL to 7.5 Log₁₀ IU/mL.

The NeuMoDx HIV-1 Quant Assay demonstrated excellent robust quantification linearity over a wide dynamic range (6 log units) with ULoQ determined at 7.5 Log₁₀ IU/mL.



| NeuMoDx HIV-1 Assay Linearity in Plasma | | | | | |
|---|-----------|--------------------------------------|--------------------|---------------|------------------------------|
| Target Conc. (Log ₁₀ IU/mL) | Replicate | Mean Conc. (Log ₁₀ IU/mL) | Standard Deviation | Absolute Bias | Total Analytical Error (TAE) |
| 7.52 | 3 | 7.54 | 0.01 | 0.01 | 0.04 |
| 6.52 | 3 | 6.55 | 0.03 | 0.02 | 0.09 |
| 5.52 | 3 | 5.52 | 0.06 | 0.00 | 0.12 |
| 4.52 | 3 | 4.52 | 0.03 | 0.01 | 0.05 |
| 3.52 | 3 | 3.49 | 0.02 | 0.03 | 0.00 |
| 2.52 | 3 | 2.45 | 0.01 | 0.07 | 0.06 |
| 1.52 | 3 | 1.52 | 0.07 | 0.00 | 0.14 |
| 1.22 | 10 | 1.25 | 0.12 | 0.03 | 0.26 |

Analytical Specificity – Cross-Reactivity


The analytical specificity of the NeuMoDx HIV-1 Quant Assay was evaluated with HIV-1 negative plasma spiked with 34 non-target (or phylogenetically similar) organisms found in blood/plasma specimens at high concentrations as indicated in the table. No cross-reactivity was observed in any of the organisms listed in the table – demonstrated 100% analytical specificity.

| NeuMoDx HIV-1 Quant Assay Analytical Specificity | | | |
|--|------------------|------------------------------|------------------|
| Pathogen Name | Concentration | Pathogen Name | Concentration |
| Cytomegalovirus | 1E6 cp/mL | Hepatitis A | 1E6 TCID50/mL |
| Epstein-Barr virus | 1E6 cp/mL | Hepatitis B | 1E6 IU/mL |
| Human Herpesvirus 6B | 1E6 cp/mL | Hepatitis C | 1E6 IU/mL |
| Human Herpesvirus 8 | 1E6 cp/mL | Zika virus | 1E6 TCID50/mL |
| Rubella | 1.14E5 TCID50/mL | Yellow Fever | 1E6 TCID50/mL |
| Human adenovirus 2 | 3.58E4 TCID50/mL | Dengue 3 | 6.36E4 TCID50/mL |
| Human adenovirus 5 | 1E6 TCID50/mL | St louis encephalitis | 1E6 cp/mL |
| Human Herpesvirus 7 | 1E6 TCID50/mL | Dengue 1 | 1E6 TCID50/mL |
| Dengue 4 | 1E6 TCID50/mL | Human T-lymphotropic virus 1 | 1E6 VP/mL |
| Parvo B19 | 1E6 IU/mL | Human T-lymphotropic virus 2 | 1E6 VP/mL |
| Dengue 2 | 1E6 TCID50/mL | Influenza A | 1E6 CEID50/mL |
| Human Immunodeficiency virus 2 | 1E6 cp/mL | Candida albicans | 8.1E6 CFU/mL |
| Human papillomavirus 16 | 1E6 cp/mL | Chlamydia Trachomatis | 1E6 B/mL |
| Human papillomavirus 18 | 1E6 cp/mL | Herpes Simplex virus 1 | 1E6 cp/mL |
| Neisseria Gonorrhoeae | 8.4E6 CFU/mL | Herpes Simplex virus 2 | 1E6 cp/mL |
| Propionibacterium acnes | 6E6 CFU/mL | Staphylococcus aureus | 8.7E6 CFU/mL |
| West Nile | 1 ng/mL | Staphylococcus epidermidis | 8.7E6 CFU/mL |

Method Correlation

The quantitative performance of the NeuMoDx HIV-1 Quant Assay was assessed against a FDA approved comparator assay. Testing was performed internally at NeuMoDx through a single-blinded study using 77 de-identified residual clinical HIV-positive specimens obtained from reference laboratories. Specimens within the linear range common to both assays were used for the linear regression analysis as shown below.

In addition to providing excellent sensitivity, the NeuMoDx HIV-1 Quant Assay demonstrated excellent quantitative correlation with the reference test.



| | | Comparator | | |
|---------|-------------|------------|-----|-------|
| | | Pos | Neg | Total |
| NeuMoDx | Pos | 73 | 0 | 73 |
| | Neg | 1 | 3 | 4 |
| | Total | 74 | 3 | 77 |
| | Sensitivity | 99% | | |

ACKNOWLEDGMENTS

This work has been supported in whole or part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Contract Number NOI-AI-85341. We would like to express our gratitude to the External Quality Assurance Program Oversight Laboratory (EQAPOL) and the source contributors, as well as NIH AIDS program for providing HIV-1 isolates for this study.

The NeuMoDx HIV-1 Quant Assay is For Research Use Only. Not for use in diagnostic procedures